- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02546947
Monitoring in Intensive Care Unit of Neuromuscular Blocking Agents Used for Acute Respiratory Distress Syndrome After Cardiothoracic Surgery (CURAREA)
Monitoring in Intensive Care Unit of Neuromuscular Blocking Agents (NMBA) Used for Acute Respiratory Distress Syndrome (ARDS) After Cardiothoracic Surgery
Mortality in Acute Respiratory Distress Syndrome (ARDS) is high (40 to 60 %). Protective mechanical ventilation is the cornerstone of the ARDS therapeutic strategies. Recently, a prospective multicenter study demonstrates that short-term infusion of neuromuscular blocking agents (NMBA) reduces hospital mortality. However, the mechanisms through which NMBAs could improve survival remain speculative and the dose of NMBA needed to observe a beneficial effect is still debated. In hypoxemic ventilated patients, continuous cisatracurium infusion with an objective of no response at orbicularis oculi to train-of-four (TOF) stimulation and an objective of two responses had similar effects on respiratory parameters. In their study, Papazian and colleagues used cisatracurium with an initial standard dose of 15 mg followed by a continuous infusion of 37.5mg/h, based on previous results of studies with patients monitored for paralysis. Atracurium and its stereoisomer cisatracurium are non-depolarizing neuromuscular blocking drugs, both used in anaesthesia and intensive care units.
The aim of this study was to compare in ARDS patients a dose adjustment of continuous-atracurium intravenous infusion with an end point of one or two response at orbicularis oculi to TOF stimulation, and a dose adjustment to achieve clinical goals of protective ventilation without monitoring of TOF stimulation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Le Plessis Robinson, France, 92350
- Centre Chirurgical Marie Lannelongue
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ARDS with a PaO2 / FiO2 < 200 with a PEEP > 5 since less than 48 hrs
- Informed consent
Exclusion Criteria:
- NMBA allergy
- Continuous administration of NMBA for ARDS prior inclusion
- Age < 18 yrs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Appropriate clinical group
group of patients with clinical dose adjustment
|
|
Active Comparator: TOF adapted group
group with an objective of less than 2 responses to TOF stimulation monitored
|
with an end point of one or two response at orbicularis oculi to TOF stimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cumulative total dose of atracurium (mg per kg per hour, administered from the initial phase of ARDS until disruption ≥48 hours)
Time Frame: 2 years
|
was the primary outcome, calculated by the following formula:(Initial bolus dose +(standard bolus dose x number of repetition doses)+cumulative continuous infusion dose (mg/h x number of hours))/ weight (kg) x duration of administration (hour).
|
2 years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-A00067-38
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, Clermont-FerrandWithdrawn
-
China-Japan Friendship HospitalNot yet recruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
-
Dr. Behcet Uz Children's HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory Failure | Pediatric Acute Respiratory Distress Syndrome (PARDS)Turkey
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Intermountain Health Care, Inc.UnknownRespiratory Failure | Acute Respiratory Distress Syndrome (ARDS) | Acute Lung Injury (ALI)United States
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Western University, CanadaEnrolling by invitationCOVID-19 Acute Respiratory Distress SyndromeCanada
-
Ain Shams UniversityCompletedCOVID-19 Acute Respiratory Distress SyndromeEgypt
Clinical Trials on Train of four monitoring
-
Ankara City Hospital BilkentRecruitingPostoperative Residual Curarization | GeriatricsTurkey
-
Mayo ClinicCompletedNeuromuscular BlockadeUnited States
-
Poitiers University HospitalCompletedPostoperative Residual CurarizationFrance
-
NorthShore University HealthSystemT4 AnalyticsTerminatedResidual Neuromuscular BlockadeUnited States
-
University of MinnesotaWithdrawnObservation of Neuromuscular Block
-
Air Force Military Medical University, ChinaCompleted
-
NYU Langone HealthCompletedMuscle Relaxation | Neuromuscular BlockadeUnited States
-
Dr. Negrin University HospitalNot yet recruitingResidual Neuromuscular Block in the Post-Anesthetic Unit and Postoperative Complications (Porcerito)Postoperative Complications | Postoperative Neuromuscular BlockSpain
-
Ankara City Hospital BilkentNot yet recruitingRocuronium | Rapid Sequence Induction | Rapid Sequence IntubationTurkey
-
Mahidol UniversityRecruitingGynecologic Cancer | Frailty | General Anesthetic Drug Adverse Reaction | Neuromuscular Blockade | Surgical ComplicationThailand